Nat Prod Sci.  2018 Mar;24(1):21-27. 10.20307/nps.2018.24.1.21.

The Amelioration Effect of the Ethanolic Extract of Cnidium officinale in Mice with Imiquimod-induced Psoriasis-like Skin Lesion

• Lee YJ
• Hong IK
• Kim H
• Heo SI
• Kwon DJ
• Ahn WG
• Kim YH
• Seo EJ
• Han SI
• Cho HJ
• Kim SY
• Yang H

• KMID: 2409605
• DOI: http://doi.org/10.20307/nps.2018.24.1.21

Abstract

Psoriasis is an auto-immune skin disease, which is characterized by the excessive generation of plaques on the skin with typically a long-lasting red, itchy and scaly symptoms. Imiquimod, which has been used for the treatment of external genital warts, actinic keratosis, and superficial basal cell carcinoma, induced of psoriasis-like skin disorders with skin erythema and thickness in mice. In the present study, we tried to find the bioactive herbal extract against imiquimod-induced psoriasis-like skin disorder in mice. During the searching of the herbal extract with anti-psoriatic effect, the ethanolic extract of Cnidium officinale ameliorated imiquimodinduced psoriasis-like skin disorder in mice. The morphological evaluation, H&E staining and Psoriasis Area and Severity Index (PASI) score showed that ear and back thickness, and erythema induced by imiquimod were significantly reversed after the treatment of the cream of the ethanolic extract of C. officinale. The overexpressed myeloperoxidase (MPO) and keratin 6A levels were decreased by the treatment of C. officinale cream. Also, IFN-γ, c-fos and IκB-α mRNA levels, which are related to the progression of psoriasis, were reduced by C. officinale cream. Thus, the ethanolic extract of C. officinale ameliorated psoriasis-like skin disorder induced by imiquimod and might be the therapeutic agent for psoriasis.

Keyword

Psoriasis; Cnidium officinale; Imiquimod

MeSH Terms

Animals
Carcinoma, Basal Cell
Cnidium*
Condylomata Acuminata
Ear
Erythema
Ethanol*
Keratin-6
Keratosis, Actinic
Mice*
Peroxidase
Psoriasis
RNA, Messenger
Skin Diseases
Skin*
Ethanol
Keratin-6
Peroxidase
RNA, Messenger

Figure

• 

  Fig. 1 HPLC chromatogram of Cnidium rhizome and two chemical markers obtained at 290 nm. (a): the water extract of Cnidium rhizome (10 mg/mL); (b): Z-ligustilide; (c): senkyunolide A.

• 

  Fig. 2 COE (the cream formulation of the 70% ethanolic extract of C. officinale) ameliorates IMQ-induced psoriasis-like lesion on back skin and ear of BALB/c mice. The experiments were performed as described in material and methods. a, mice were treated daily with vehicle cream, COE, IMQ cream, IMQ + CLO cream, IMQ + TAC cream and IMQ + COE on the shaved back skin and ear. b, the cumulative scores (%) of thickness and erythema of back skin and ear for 6 days, respectively, relative to 0 day. c, the PASI scores were measured as the sum of the ear and back thickness, and erythema according to PASI index (http://pasi.corti.li, ver 1.7.1) after the final administration. Symbols indicate mean score ± SEM of six groups, n = 6/group. *p < 0.05 indicates a statistically significant difference from the IMQ group.

• 

  Fig. 3 COE alters keratinocyte proliferation and differentiation. H&E staining (× 100) of back skin (a) and ear (b). Mice were treated daily with vehicle cream, COE, IMQ cream, IMQ + CLO cream, IMQ + TAC cream and IMQ + COE for 6 days. K: keratin of stratum corneum, E: epidermis, HF: hair follicles, D: dermis and SC: subcutis.

• 

  Fig. 4 COE alters the expression of keratin 6A of back skin (a) and ear (b), and MPO of back skin (c) and ear (d) (IHC, × 100). Mice were treated daily with vehicle cream, COE, IMQ cream, IMQ + CLO cream, IMQ + TAC cream and IMQ + COE for 6 days.

• 

  Fig. 5 COE reduced the expression of IFN-γ, c-fos and IκB-α induced by IMQ. Mice were treated daily with vehicle cream, COE, IMQ cream and IMQ + COE for 6 days. RNA was extracted from back skin after sacrifice. The expression of IFN-γ, c-fos and IκB-α was determined by RT-PCR and their levels were represented relative to β-actin levels in an individual mouse (n = 6).

Reference

1. Sakkas LI, Bogdanos DP. Autoimmun Rev. 2017; 16:10–15.

2. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JYM, Elmets CA, Korman NJ, Beutner KR, Bhushan R. J Am Acad Dermatol. 2008; 58:826–850.

3. Zhang CS, Yu JJ, Parker S, Zhang AL, May B, Lu C, Xue CC. Int J Dermatol. 2014; 53:1305–1318.

4. Deng S, May BH, Zhang AL, Lu C, Xue CCL. Br J Dermatol. 2013; 169:769–782.

5. OuYang Q, Pan Y, Luo H, Xuan C, Liu J, Liu J. Int Immunopharmacol. 2016; 39:369–376.

6. van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E. J Immunol. 2009; 182:5836–5845.

7. Choi HS, Kim MSL, Sawamura M. Flavour Fragr J. 2002; 17:49–53.

8. Bae KE, Choi YW, Kim ST, Kim YK. Molecules. 2011; 16:8833–8847.

9. Ramalingam M, Park YK. Pharmacogn Mag. 2010; 6:323–330.

10. Wu Z, Uchi H, orino-Koga S, Nakamura-Satomura A, Kita K, Shi W, Furue M. Exp Dermatol. 2014; 23:260–265.

11. Wu Z, Uchi H, Morino-Koga S, Shi W, Furue M. Exp Dermatol. 2015; 24:703–708.

12. Vincent N, Ramya DD, Vedha HB. Dermatol Reports. 2014; 6:5451.

13. Mommers JM, van Rossum MM, van Erp PEJ, Van de Kerkhof PCM. Dermatology. 2000; 201:15–20.

14. Buates S, Matlashewski G. J Infect Dis. 1999; 179:1485–1494.

15. Palfreeman AC, McNamee KE, McCann FE. Drug Des Devel Ther. 2013; 7:201–210.

16. Nestle FO, Kaplan DH, Barker J. N Engl J Med. 2009; 361:496–509.

17. Hou R, Li J, Niu X, Liu R, Chang W, Zhao X, Wang Q, Li X, Yin G, Zhang K. J Dermatol Sci. 2017; 86:181–186.

18. Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U. Br J Clin Pharmacol. 2012; 74:424–436.

19. Bello I, Shehu MW, Musa M, Asmawi MZ, Mahmud R. J Ethnopharmacol. 2016; 189:253–276.

20. Choudhry SZ, Bhatia N, Ceilley R, Hougeir F, Lieberman R, Hamzavi I, Lim HW. J Drugs Dermatol. 2014; 13:148–153.

21. Lee YM, Kim NH, Lee MR. Nat Prod Sci. 2015; 21:122–127.

22. Belcaro G, Maquart FX, Scoccianti M, Dugall M, Hosoi M, Cesarone MR, Luzzi R, Cornelli U, Ledda A, Feragalli B. Panminerva Med. 2011; 53:105–118.

23. Jeong JB, Ju SY, Park JH, Lee JR, Yun KW, Kwon ST, Lim JH, Chung GY, Jeong HJ. Cancer Epidemiol. 2009; 33:41–46.

24. Jeong JB, Park JH, Lee HK, Ju SY, Hong SC, Lee JR, Chung GY, Lim JH, Jeong HJ. Food Chem Toxicol. 2009; 47:525–529.

25. Cao LY, Soler DC, Debanne SM, Grozdev I, Rodriguez ME, Feig RL, Carman TL, Gilkeson RC, Orringer CE, Kern EF, McCormick TS, Cooper KD, Korman NJ. Am J Transl Res. 2013; 6:16–27.

26. Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. J Invest Dermatol. 2001; 116:633–640.